Trastuzumab deruxtecan ups PFS in HER2+ metastatic breast cancer

For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of progression or death from any cause is lower with trastuzumab ...

Oncology & Cancer

Promising advances in the treatment of metastatic breast cancer

During the virtual 2021 Annual Congress of the European Society for Medical Oncology (ESMO), 16-21 September, research (co) led by VHIO investigators revealed promising advances in the treatment of metastatic breast cancer. ...


New treatment method for breast cancer with less side effects

Thomas Hatschek, associate professor at the department of Oncology-Pathology, together with colleagues, has recently published an article in JAMA Oncology showing that a new treatment for breast cancer with an antibody linked ...

page 1 from 7